Coinfection of COVID-19 and viral hepatitis: A rapid review

Laith A. I. K. Al-Kaif; Mohammad A. K. Al-Saadi; Alaa H. Al-Charrakh

doi:10.53730/ijhs.v6nS3.7016

Authors

Laith A. I. K. Al-Kaif Department of Microbiology, College of Medicine, University of Babylon, Babylon, Hilla, Iraq | Dept. of Medical Laboratory Techniques, Al Mustaqbal University College, Babylon province, Iraq
Mohammad A. K. Al-Saadi Dept. of Microbiology/ College of Medicine / University of Babylon, Hilla, Iraq
Alaa H. Al-Charrakh
ahani67@gmail.com
Dept. of Microbiology/ College of Medicine / University of Babylon, Hilla, Iraq

Keywords:

SARS-CoV-2, viral hepatitis, acute and chronic liver or respiratory disease

Abstract

The purpose of this rapid review is to investigate the development of the hepatic manifestations and challenges with SARS-COV-2 and multiple viral hepatitis infections. The literature on the most critical viral, genetic and immunological factors between SARS-CoV-2 and viral hepatitis was reviewed, and the most important interactions that occur with the host were identified in addition to the use of antivirals, another drug, and also the potential of defective viral genomes in antiviral inhibitors. This review specified that some types of viral hepatitis in SARS-COV-2 patients may be reduced reactivation and receive immunosuppressive therapy. We concluded from the current review that it is necessary to consider the special care of persons exposed to infection with SARS-CoV-2 to persons infected with viral hepatitis. In particular, advanced cases of the disease and their stages of treatment as it leads to liver dysfunction and life-threatening patient.

Downloads

Download data is not yet available.

References

Abdul Amir, Y. F. (2018). Genetic polymorphisms of some interferons associated with chronic viral hepatitis B and C. Ph.D thesis, College of Medicine, Babylon University, Iraqi.

Abdul-Husin, I. F. (2013). Epidemiological Study of Viral Hepatitis Types B and C in Babylon Province. M.Sc thesis, College of Medicine, University of Babylon.

Agarwal, A., Chen, A., Ravindran, N., To, C., & Thuluvath, P.J. (2020). Gastrointestinal and Liver Manifestations of COVID-19. J Clin Exp Hepatol., 10, 263-65.

Akkaif, M.A., Daud, N.A.A., Sha’aban, A., Ng, M.L., Abdul Kader, M.A.S., Noor, D.A.M. & Ibrahim, B. (2021). The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD). Molecules, 26, 1987.

Akkaif, M.A., Ng, M.L., Kader, M.A.S.A., Daud, N.A.A., Sha’aban, A. & Ibrahim, B. (2021). A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Pharmacological Reports, 1-14.

Akkaif, M.A., Sha’aban, A., Daud, N.A.A., Ng, M.L. & Ibrahim, B. (2020). Investigate the Strategy of Using Pharmacogenetics and Pharmacometabonomics to the Personalization of Ticagrelor Antiplatelet Therapy. Syst. Rev. Pharm., 11, 1100-07.

Akkaif, M.A., Sha’aban, A., Daud, N.A.A., Yunusa, I., Ng, M.L., SK Abdul Kader, M.A., Noor, D.A.M. & Ibrahim, B. (2021). Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovascular Development and Disease, 8, 123.

Aldhaleei, W.A., Alnuaimi, A., & Bhagavathula, A.S. (2020). COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates. Cureus, 12(6), e8645.

Al-Sadeq, D. W., Taleb, S. A., Zaied, R. E., Fahad, S. M., Smatti, M. K., Rizeq, B. R., & Nasrallah, G. K. (2019). Hepatitis B virus molecular epidemiology, host-virus interaction, coinfection, and laboratory diagnosis in the MENA region: An update. Pathogens, 8(2).

Bangash, M. N., Patel, J., & Parekh, D. (2020). COVID-19 and the liver: little cause for concern. The lancet. Gastroenterology & hepatology, 5(6), 529.‏

Belizário, J. E., Neyra, J. M., & Rodrigues, M.F.S.D. (2018). When and how NK cell-induced programmed cell death benefits immunological protection against intracellular pathogen infection. Innate Immunity, 24(8), 452-65.

Botelho-Souza, L.F., Vasconcelos, M.P.A., dos Santos, A.d.O., Salcedo, J.M.V. & Vieira, D.S. (2017). Hepatitis delta: virological and clinical aspects. Virology Journal, 14:177.

Cai, Q., Huang, D., Yu, H., & et al. (2020). COVID-19: abnormal liver function tests. J Hepatol., 73(3):566e574.

Cano, A., Cifuentes, L., & Amariles, P. (2017). Structured Literature Review of Hepatic Toxicity Caused by Medicines. Revista colombiana de Gastroenterología, 32(4), 337-48.

Carroll, M.B. (2011). The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther., 11, 533–44.

Cella, M., Miler, H., & Song, C. (2014). Beyond NK cells: the expanding universe of innate lymphoid cells. Front Immunol., 5, 1–11.

Chai, X., Hu, L., Zhang, Y., et al. (2019). Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. https://doi.org/10.1101/2020.02.03.931766

Chang, Y., Jeong, S.W., & Jang, J.Y. (2022) Hepatitis B Virus Reactivation Associated With Therapeutic Interventions. Front. Med. 8: 770124, 1-9.

Chau, T.N., Lee, K.C., Yao, H., Tsang, T.Y., Chow, T.C., Yeung, Y.C., Choi, K.W., Tso, Y.K., Lau, T., Lai, S.T., & Lai, C.L. (2004). SARS-Associated Viral Hepatitis Caused by a Novel Coronavirus: Report of Three Cases. Hepatology, (39)2, 302-10.

Chen, J., Dai, L., Barrett, L., et al. (2020). SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. bioRxiv., 4(1), 1-6.

Chen, L.F., Mo, Y.Q., Jing, J., et al. (2017). Short-course tocilizumab increases

risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis., 20:859-69.

Fan, Z., Chen, L., Li, J., & et al. (2020). Clinical features of COVID-19-related liver damage. Clin Gastroenterol and Hepatol., 18, 1561-66.

Farci, P. and Niro, G.A. (2018). Current and Future Management of Chronic Hepatitis D. Gastroenterology & Hepatology, 14( 6), 342-51.

Feinstone, S.M. (2019). History of the Discovery of Hepatitis A Virus. s Cold Spring Harb Perspect Med; 9, a031740.

Fonseca and Ferrazda, J.C. (2010). History of viral Hepatitis. Review of Society Medicine. 43(3), 322-30.

George, J., Liddle, C., Murray, M., Byth, K. & Farrell, G.C. (1995). Pre-translational regulation of cytochrome P450 genes is responsible for disease specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol., 49, 873-81.

George, J., Murray, M., Byth, K. & Farrell, G.C. (1995). Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology., 21, 120-28.

Guengerich, F.P. & Turvy, C.G. (1991). Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther., 256, 1189-94.

Jefferies, M., Rauff, B., Rashid, H., Lam, T., & Rafiq, S. (2018). Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases, 6(13), 589-99

Khuroo, M.S., (2011 ). Discovery of hepatitis E: The epidemic non-A, non-B hepatitis 30 years. Virus Research.161 (1), 3-14

Kumar, A., Singh, R., Kaur, J., Pandey, S., Sharma, V., Thakur, L., Sati, S., Mani, S., Asthana, S., Sharma, T.K., Chaudhuri, S., Bhattacharyya, S. and Kumar, N. (2021). Wuhan to World: The COVID-19 Pandemic. Front. Cell. Infect. Microbiol. 11, 596201.

Lehmann, A., & Matoba, A. (2018). Reactivation of herpes zoster stromal keratitis after HZ/su adjuvanted herpes zoster subunit vaccine. Ophthalmology, 125(11), 1682.

Lensen, R., Netea, M.G., and Rosendaa, F.R. (2021). Hepatitis C Virus Reactivation Following COVID19 Vaccination – A Case Report. International Medical Case Reports Journal, 14, 573-76.

Lin, Y., Yuan, J., Long, Q., Hu, J., Deng, H., Zhao, Z., Chen, J., Lu, M., & Huang, A. (2021). Patients with SARS-CoV-2 and HBV coinfection are at risk of greater liver injury. Genes & Diseases, 8(4), 484-92.

Liu, J., Wang, T., Cai, Q., Sun, L., Huang, D., Zhou ,G., He, Q., Wang, F.S., Liu, L., & Chen, J. (2020). Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection. Hepatol Res., 50, 1211-21.

Liu, R., Zhao, L., Cheng, X., Han, H., Li, C., Li, D., Liu, A., Gao, G., Zhou, F., Liu, F., Jiang, Y., Zhu, C., & Xia, Y. (2021). Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int., 41, 720-30.

Liu, S., Zhou, B., Valdes, J. D., Sun, J., & Guo, H. (2019). Serum hepatitis B virus

RNA: a new potential biomarker for chronic hepatitis B virus infection. Hepatology, 69(4), 1816-27.

Lown, K., Kolars, J., Turgeon, K., Merion, R., Wrighton, S.A. & Watkins, P.B. (1992). The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther., 51, 229-38.

McArdle A.J., Turkova A., & Cunnington A.J. (2018). When do coinfections matter? Curr. Opin. Infect. Dis. 2018; 31(3): 209–15.

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J.J. (2020). COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. Lancet, 395, 1033–34.

Mirzaei, H., Vahidi, M., Shokoohi, M., Darvishian, M., Sharifi, H., Sharafi, H., & Karamouzian, M. (2021). COVID-19 among patients with hepatitis B or hepatitis C: A systematic review. Hepat. Mon., 20(11): e111617.

Morgan, D.J. & McLean, A.J. (1995). Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet., 29: 370-91.

Pascarella, S. & Negro, F. (2011). Hepatitis D virus: an update. Liver International. 31(1), 7–21.

Premkumar, M. & Kedarisetty, C.K. (2021). Cytokine storm of COVID-19 and its impact on patients with and without chronic liver disease. J Clin Transl Hepatol., 9(2), 256–64.

Reddy, K.R. (2020). SARS-CoV-2 and the Liver: Considerations in Hepatitis B and Hepatitis C Infections. Clinical Liver Disease, 15(5): 191-194.

Reddy, K.R., Beavers, K.L., Hammond, S.P., et al. (2015). American

Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology, 148, 215-19.

Rodriguez-Tajes, S., Miralpeix, A., Costa, J., Lopez-Sune, E, Laguno, M., Pocurull, A., & et al. (2021). Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat., 28: 89–94.

Shackel, N.A., Patel, K., & McHutchison, J. (2013). Chapter 99 - Viral Hepatitis, Editor(s): Geoffrey S. Ginsburg, Huntington F. Willard, Genomic and Personalized Medicine (Second Edition), Academic Press. P, 1173-90.

Tang, L.S.Y., Covert, E., Wilson, E. & Kottilil, S. (2018). Chronic hepatitis B infection: a review. JAMA., 319:1802–13.

Terrault, N.A., Lok, A.S., McMahon, B.J., et al. (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis

B guidance. Hepatology, 67, 1560-99.

Webb, G.W. & Dalton, H.R. (2019). Hepatitis E: an underestimated emerging threat. Therapeutic Advances in Infectious Disease. 6, 1–18.

Xu, Z., Shi, L., Wang, Y., & et al. (2020). Pathological findings of COVID‐19 associated with acute respiratory distress syndrome. Lancet Respir Med., 8, 420‐22.

Zarrin A, & Akhondi H (2022). Viral Hepatitis. In: StatPearls [Internet]. Treasure Island (FL).

Zhang, B., Huang, W., & Zhang, S. (2020). Clinical Features and Outcomes of Coronavirus Disease 2019 (COVID-19) Patients With Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol., 18, 2633-37.

Zhang, C., Shi, L., & Wang, F.S. (2020). Liver injury in COVID‐19: management and challenges. Lancet Gastroenterol Hepatol; 5, 428‐30.

Zhang, J., Wang, X., Jia, X., et al. (2020). Risk factors for disease severity, improvement, and mortality of COVID-19 patients in Wuhan, China. Clin Microbiol Infect; 26(6), 767-72.

Zhang, X., Guan, L., Tian, H., Zeng, Z., Chen, J., Huang, D., Sun, J., Guo, J., Cui, H., & Li, Y. (2021). Risk Factors and Prevention of Viral Hepatitis Related Hepatocellular Carcinoma. Front. Oncol. 11, 686962.

Zhou, F., Yu, T., Du, R., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395, 1054-62.

Zou, X., Fang, M., Li, S., et al. (2020). Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. Clin Gastroenterol Hepatol., S1542-3565, 30821.